Characterization of pediatric extrathoracic aerosol deposition with air-jet dry powder inhalers

Abstract

The use of air-jet dry powder inhalers (DPIs) offers a number of advantages for the administration of pharmaceutical aerosols, including the ability to achieve highly efficient and potentially targeted aerosol delivery to the lungs of children using the oral or trans-nasal routes of administration. To better plan targeted lung delivery of pharmaceutical aerosols with these inhalers, more information is needed on the extrathoracic (ET) depositional loss in pediatric subjects when using relatively small (e.g., 0.5–2 μm) particles and including oral or nasal device interfaces. The objective of this study was to implement validated computational fluid dynamics (CFD) models to characterize ET depositional loss during mouth-throat (MT) and nose-throat (NT) aerosol administration to pediatric subjects (2–10 years old) using an air-jet DPI platform across a range of initial small-particle aerosol sizes (0.41–13.65 μm) and inhalation flow rates (8–20 L/min).

A new CFD model focused on small-particle aerosol depositional loss in existing pediatric airway models was developed and validated with existing in vitro data. The validated CFD model was then used to characterize depositional loss in the MT and NT regions of children using particle sizes, flow rates and interfaces consistent with air-jet DPIs.

Successful validation of the CFD model for small-particle aerosol deposition was achieved through enhanced resolution of the near-wall transport conditions. Existing non-dimensional parameters were used to produce high quality single-curve deposition efficiency correlations with r² values in the range of 0.95–0.97. A new method for predicting realistic polydisperse aerosol deposition using the developed correlations and an equivalent monodisperse particle diameter was also introduced. In conclusion, the newly developed correlations will be useful in planning the lung delivery of next-generation inhaled medications, where achieving both low ET loss and targeted airway deposition, perhaps with excipient enhanced growth technology, are critical factors.